Cover Image
市場調查報告書

眼科用醫藥品的全球市場:抗青光眼藥·乾眼症治療藥·其他 (視網膜障礙·抗感染疾病藥/過敏)

Ophthalmology Drugs Market Global Report 2017 - Including Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)

出版商 The Business Research Company 商品編碼 531334
出版日期 內容資訊 英文 125 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
眼科用醫藥品的全球市場:抗青光眼藥·乾眼症治療藥·其他 (視網膜障礙·抗感染疾病藥/過敏) Ophthalmology Drugs Market Global Report 2017 - Including Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
出版日期: 2017年07月17日 內容資訊: 英文 125 Pages
簡介

本報告提供全球眼科用醫藥品的市場調查,提供市場定義和概要,市場的各種影響因素分析,各藥物部門·各地各國趨勢與市場規模的變化與預測,並彙整與宏觀經濟因素·醫療保健市場全體·各種產業指標的比較,競爭環境,企業簡介等資料。

第1章 市場特徵

第2章 市場規模·成長率

  • 市場成長:迄今的過程
    • 成長推進因素
    • 阻礙成長要素
  • 市場成長:預測
    • 成長推進因素
    • 阻礙成長要素

第3章 大環境分析

第4章 客戶資訊

第5章 眼科用醫藥品市場分析:各種類

  • 全球市場的實際成果:各種類
    • 抗青光眼藥
    • 乾眼症治療藥
    • 其他
      • 視網膜障礙
      • 抗感染疾病藥/過敏
  • 全球市場的變化與預測:各種類
  • 市場趨勢·策略

第6章 眼科用醫藥品市場分析:各地各國分析

  • 全球市場的實際成果:各地區
  • 全球市場的變化與預測:各地區
  • 市場實際成果:各國
  • 市場變化與預測:各國
  • 全球醫藥品市場實際成果:部門·各地區
  • 全球醫藥品市場實際成果:部門·各國

第7章 宏觀經濟因素與市場比較

  • 市場規模的佔 GDP的百分比
  • 平均每個人的平均支出額

第8章 宏觀經濟因素與市場比較:各國

  • 市場規模的佔 GDP的百分比:各國
  • 平均每個人的平均支出額:各國

第9章 產業指標與市場比較

  • 全球藥劑師數:各國
  • 市場收益 vs 藥劑師數:各國
  • 全球醫藥品公司數:各國
  • 市場收益 vs 醫藥品公司數:各國
  • 全球對R&D/產品開發的平均支出額:各國
  • 市場收益 vs 對R&D/產品開發的平均支出額:各國
  • 全球非專利&品牌銷售額的比例:各國
  • 市場收益 vs 非專利&品牌銷售額的比例:各國
  • 青光眼的患病人數:各國

第10章 亞太地區市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 中國
  • 印度
  • 日本
  • 澳洲

第11章 西歐市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙

第12章 東歐市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 俄羅斯

第13章 北美市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 美國

第14章 南美市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 巴西

第15章 中東市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類

第16章 非洲市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類

第17章 競爭環境

  • 企業簡介
  • Novartis Ag
  • Regeneron
  • Allergan
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.

第18章 主要M&A:眼科用醫藥品市場

第19章 市場背景:醫藥品市場

第20章 醫藥品產業的Financial Margins

第21章 附錄

目錄

Development of combination therapies for the treatment of eye related diseases including glaucoma is an emerging trend in the market. For instance, in September 2013, Alcon (a subsidiary of Novartis) received FDA approval for commercialization of its Simbrinza, a fixed dose combination drug without beta blocker used for the treatment of glaucoma.

The Ophthalmology Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global ophthalmology drugs sector.

Where is the largest and fastest growing market for the ophthalmology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ophthalmology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
  • The ophthalmology drugs market section of the report gives context. It compares the ophthalmology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Ophthalmology Drugs Indicators Comparison.
  • The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope:

Markets Covered: Glaucoma, Dry Eye, Others (Retinal Disorders, Anti-Infectives/Allergy)

Companies Mentioned: Novartis AG, Regeneron, Allergan, F. Hoffmann-La Roche Ltd, and Pfizer Inc.

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Ophthalmology Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Reasons to Purchase:

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Gain a global perspective on the development of the market.
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Table of Contents

1. Ophthalmology Drugs Market Characteristics

2. Ophthalmology Drugs Market Size And Growth

  • 2.1. Historic Market Growth
    • 2.1.1. Drivers Of The Market
    • 2.1.2. Restraints On The Market
  • 2.2. Forecast Market Growth
    • 2.2.1. Drivers Of The Market
    • 2.2.2. Restraints On The Market

3. Pestle Analysis

  • 3.1. Political
  • 3.2. Economic
  • 3.3. Social
  • 3.4. Technological
  • 3.5. Legal
  • 3.6. Environmental

4. Ophthalmology Drugs Market Customer Information

5. Ophthalmology Drugs Market Segmentation

  • 5.1. Global Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
  • 5.2. Global Ophthalmology Drugs Market, 2012 - 2020, Historic And Forecast, By Segment
  • 5.3 Global Ophthalmology Drugs Market Trends And Strategies

6. Ophthalmology Drugs Market Regional And Country Analysis

  • 6.1. Global Ophthalmology Drugs Market, 2016, By Region
  • 6.2. Global Ophthalmology Drugs Market, 2012 - 2020, Historic And Forecast, By Region
  • 6.3. Ophthalmology Drugs Market, 2016, By Country
  • 6.4. Ophthalmology Drugs Market, 2012 - 2020, Historic And Forecast, By Country
  • 6.5. Global Pharmaceutical Market Segments, 2016, By Region
  • 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region
  • 6.7. Global Pharmaceutical Market Segments, 2016, By Country
  • 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country

7. Global Ophthalmology Drugs Market Comparison With Macro Economic Factors

  • 7.1. Ophthalmology Drugs Market Size, Percentage Of GDP, Global
  • 7.2. Per Capita Average Ophthalmology Drugs Expenditure, Global

8. Ophthalmology Drugs Market Comparison With Macro Economic Factors Across Countries

  • 8.1. Ophthalmology Drugs Market Size, Percentage Of GDP, By Country
  • 8.2. Per Capita Average Ophthalmology Drugs Expenditure, By Country

9. Ophthalmology Drugs Market Comparison With Industry Metrics

  • 9.1. Global Number Of Pharmacists, 2016, By Country
  • 9.2. Global Ophthalmology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
  • 9.3. Global Number Of Pharma Enterprises, 2016, By Country
  • 9.4. Global Ophthalmology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
  • 9.5. Global Average Spending On R&D/Product Development, 2016, By Country
  • 9.6. Global Ophthalmology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
  • 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
  • 9.8. Global Ophthalmology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
  • 9.9. Prevalent Cases Of Glaucoma, 2014, By Country

10. Asia-Pacific Ophthalmology Drugs Market

    • 10.1.1. Asia-Pacific Ophthalmology Drugs Market Overview
    • 10.1.2. Asia-Pacific Ophthalmology Drugs Historic Market, 2012 - 2016
    • 10.1.3. Asia-Pacific Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 10.1.4. Asia-Pacific Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
  • 10.2. Asia-Pacific Ophthalmology Drugs Market: Country Analysis
  • 10.3. China Ophthalmology Drugs Market
    • 10.3.1. China Ophthalmology Drugs Market Overview
    • 10.3.2. China Ophthalmology Drugs Historic Market, 2012 - 2016
    • 10.3.3. China Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 10.3.4. China Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 10.3.5. China Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 10.3.6. China Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020
  • 10.4. India Ophthalmology Drugs Market
    • 10.4.1. India Ophthalmology Drugs Market Overview
    • 10.4.2. India Ophthalmology Drugs Historic Market, 2012 - 2016
    • 10.4.3. India Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 10.4.4. India Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 10.4.5. India Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 10.4.6. India Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020
  • 10.5. Japan Ophthalmology Drugs Market
    • 10.5.1. Japan Ophthalmology Drugs Market Overview
    • 10.5.2. Japan Ophthalmology Drugs Historic Market, 2012 - 2016
    • 10.5.3. Japan Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 10.5.4. Japan Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 10.5.5. Japan Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 10.5.6. Japan Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020
  • 10.6. Australia Ophthalmology Drugs Market
    • 10.6.1. Australia Ophthalmology Drugs Historic Market, 2012 - 2016
    • 10.6.2. Australia Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 10.6.3. Australia Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 10.6.4. Australia Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 10.6.5. Australia Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020

11. Western Europe Ophthalmology Drugs Market

    • 11.1.1. Western Europe Ophthalmology Drugs Market Overview
    • 11.1.2. Western Europe Ophthalmology Drugs Historic Market, 2012 - 2016
    • 11.1.3. Western Europe Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 11.1.4. Western Europe Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
  • 11.2. Western Europe Ophthalmology Drugs Market: Country Analysis
  • 11.3. UK Ophthalmology Drugs Market
    • 11.3.1. UK Ophthalmology Drugs Market Overview
    • 11.3.2. UK Ophthalmology Drugs Historic Market, 2012 - 2016
    • 11.3.3. UK Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 11.3.4. UK Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 11.3.5. UK Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 11.3.6. UK Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020
  • 11.4. Germany Ophthalmology Drugs Market
    • 11.4.1. Germany Ophthalmology Drugs Historic Market, 2012 - 2016
    • 11.4.2. Germany Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 11.4.3. Germany Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 11.4.4 Germany Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 11.4.5 Germany Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020
  • 11.5 France Ophthalmology Drugs Market
    • 11.5.1 France Ophthalmology Drugs Historic Market, 2012 - 2016
    • 11.5.2 France Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 11.5.3 France Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 11.5.4 France Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 11.5.5 France Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020
  • 11.6. Italy Ophthalmology Drugs Market
    • 11.6.1. Italy Ophthalmology Drugs Historic Market, 2012 - 2016
    • 11.6.2. Italy Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 11.6.3. Italy Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 11.6.4. Italy Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 11.6.5. Italy Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020
  • 11.7. Spain Ophthalmology Drugs Market
    • 11.7.1. Spain Ophthalmology Drugs Historic Market, 2012 - 2016
    • 11.7.2. Spain Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 11.7.3. Spain Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 11.7.4. Spain Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 11.7.5. Spain Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020

12. Eastern Europe Ophthalmology Drugs Market

    • 12.1.1. Eastern Europe Ophthalmology Drugs Market Overview
    • 12.1.2. Eastern Europe Ophthalmology Drugs Historic Market, 2012 - 2016
    • 12.1.3. Eastern Europe Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 12.1.4 Eastern Europe Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
  • 12.2. Eastern Europe Ophthalmology Drugs Market: Country Analysis
  • 12.3. Russia Ophthalmology Drugs Market
    • 12.3.1. Russia Ophthalmology Drugs Historic Market, 2012 - 2016
    • 12.3.2. Russia Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 12.3.3. Russia Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 12.3.4. Russia Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 12.3.5. Russia Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020

13. North America Ophthalmology Drugs Market

    • 13.1.1. North America Ophthalmology Drugs Market Overview
    • 13.1.2. North America Ophthalmology Drugs Historic Market, 2012 - 2016
    • 13.1.3. North America Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 13.1.4. North America Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
  • 13.2. North America Ophthalmology Drugs Market: Country Analysis
  • 13.3. USA Ophthalmology Drugs Market
    • 13.3.1. USA Ophthalmology Drugs Historic Market, 2012 - 2016
    • 13.3.2. USA Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 13.3.3 USA Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 13.3.4. USA Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 13.3.5. USA Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020

14. South America Ophthalmology Drugs Market

    • 14.1.1. South America Ophthalmology Drugs Market Overview
    • 14.1.2. South America Ophthalmology Drugs Historic Market, 2012 - 2016
    • 14.1.3. South America Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 14.1.4. South America Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
  • 14.2. South America Ophthalmology Drugs Market: Country Analysis
  • 14.3. Brazil Ophthalmology Drugs Market
    • 14.3.1. Brazil Ophthalmology Drugs Historic Market, 2012 - 2016
    • 14.3.2. Brazil Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 14.3.3. Brazil Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)
    • 14.3.4. Brazil Ophthalmology Drugs Percentage Of GDP, 2012 - 2020
    • 14.3.5. Brazil Per Capita Average Ophthalmology Drugs Expenditure, 2012 - 2020

15. Middle East Ophthalmology Drugs Market

    • 15.1.1. Middle East Ophthalmology Drugs Market Overview
    • 15.1.2. Middle East Ophthalmology Drugs Historic Market, 2012 - 2016
    • 15.1.3. Middle East Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 15.1.4. Middle East Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)

16. Africa Ophthalmology Drugs Market

    • 16.1.1. Africa Ophthalmology Drugs Market Overview
    • 16.1.2. Africa Ophthalmology Drugs Historic Market, 2012 - 2016
    • 16.1.3. Africa Ophthalmology Drugs Forecast Market, 2016 - 2020
    • 16.1.4. Africa Ophthalmology Drugs Market, 2016, By Segment
    • 16.1.4. Africa Ophthalmology Drugs Market, 2016, By Segment; Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)

17. Ophthalmology Drugs Market Competitive Landscape

  • 17.1. Company Profiles
  • 17.2. Novartis Ag
    • 17.2.1. Overview
    • 17.2.2. Products And Services
    • 17.2.3. Strategy
    • 17.2.4. Financial Performance
  • 17.3. Regeneron
    • 17.3.1. Overview
    • 17.3.2. Products And Services
    • 17.3.3. Strategy
    • 17.3.4. Financial Performance
  • 17.4. Allergan
    • 17.4.1. Overview
    • 17.4.2. Products And Services
    • 17.4.3. Strategy
    • 17.4.4. Financial Performance
  • 17.5. F. Hoffmann-La Roche Ltd
    • 17.5.1. Overview
    • 17.5.2. Products And Services
    • 17.5.3. Strategy
    • 17.5.4. Financial Performance
  • 17.6. Pfizer Inc.
    • 17.6.1. Overview
    • 17.6.2. Products And Services
    • 17.6.3. Strategy
    • 17.6.4. Financial Performance

18. Key Mergers And Acquisitions In The Ophthalmology Drugs Market

19. Market Background: Pharmaceutical Drugs Market

    • 19.1.1. Pharmaceutical Drugs Market Characteristics
    • 19.1.2. Pharmaceutical Drugs Market Historic Growth
      • 19.1.2.1. Drivers Of The Market
      • 19.1.2.2. Restraints Of The Market
    • 19.1.3. Pharmaceutical Drugs Market Forecast Growth
      • 19.1.3.1. Drivers Of The Market
      • 19.1.3.2. Restraints Of The Market
    • 19.1.4. Pharmaceutical Drugs Trends And Strategies
  • 19.2. Pharmaceutical Drugs Market Regional And Country Analysis
    • 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region
    • 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region
    • 19.2.3. Pharmaceutical Drugs Market, 2016, By Country
    • 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country
    • 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
    • 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
  • 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors
    • 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
    • 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global
  • 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
    • 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
    • 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country
  • 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market

20. Pharmaceuticals Industry Financial Margins

21. Appendix

  • 21.1. NAICS Definitions Of Industry Covered In This Report
  • 21.2. Abbreviations
  • 21.3. Currencies
  • 21.4. Research Inquiries
  • 21.5. The Business Research Company
  • 21.6. Copyright And Disclaimer
Back to Top